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Chemokine receptor CCRL2-V180M and its role in inflammation and Alzheimer’s disease
Lucie Dearden1, Josue D. Gonzalez Murcia PhD candidate1,2, John S. K. Kauwe PhD2, K. Scott Weber PhD1
1Department

of Microbiology and Molecular Biology, Brigham Young University; 2Department of Biology, Brigham Young University

Methods
Introduction
Alzheimer’s Disease (AD) is a fatal neurodegenerative condition that is the leading cause of
dementia among elderly patients. It is commonly associated with neuroinflammation and its
progression is evident in higher levels of serum chemokines and activated microglia. We have
identified a receptor and its mutant, CCRL2-V180M, associated with lower levels of the proinflammatory chemokine ligand, CCL4. We have previously identified ligand binding behavior of
one isoform of CCRL2, CRAM-A and propose to compare its behaviour to the more commonly
expressed isoform, CRAM-B. We hypothesize that CCRL2-V180M binds with a higher affinity than
WT to CCL4, decreasing levels of CCL4 in the CSF and offering possible protection against AD.
Characterization of CRAM-A ligand
binding

3D protein structure and hydrophilicity analyses were performed using Chimera software to
generate and compare models of CCRL2-V180M and WT.

A blocking analysis between CCRL2-WT and CCRL2-V180M and the ligand CCL4 was done using
flow cytometry and flowJo software, in order to measure receptor expression before and after
incubation with CCL4.
Binding analyses between CCRL2-WT and CCRL2-V180M were also done between chemerin, a
known ligand of the receptor, and CCL19, a proposed ligand of the receptor to evaluate binding
differences.

Characterization of CRAM-B ligand binding
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Results
Conclusions
The analysis using Chimera software shows a slight change to the N-terminus region of the protein
ribbon structure, and a decrease in hydrophobicity in CCRL2-V180M.
In the competitive binding assay we did not see a significant drop in receptor expression in CCRL2V180M or WT when both were incubated with CCL4.
We additionally saw that chemerin bound with higher affinity to CCRL2-V180M than to wild type.
In a separate binding assay where cells were incubated with CCL19, a proposed ligand of CCRL2,
we saw no difference in binding of CCL19 between CCRL2-V180M and wild type.

Neither CCRL2-V180M nor CCRL2-WT bound to CCL4, disproving our original hypothesis.
Chemerin and CCL19, natural ligands of CCRL2, both bound with higher affinity to CCRL2-V180M
than WT. We therefore hypothesize that these chemokine ligands are involved in the pathway
responsible for reducing levels of CCL4 in the CSF and offering protection against AD.

